VEGFA and neoplasm: In addition to increasing glycolysis and lactate production, bevacizumab, an anti-VEGF neutralizing antibody, can upregulate lipid metabolism pathways, resulting in spectacular changes in tumor lipid mass spectrometry, including increased triglyceride levels and decreased lipid chain saturation (65).